KRAS Vaccine + Immunotherapy for Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a special vaccine combined with immune-boosting substances and two drugs in advanced lung cancer patients with specific genetic mutations. The goal is to teach the immune system to attack the cancer cells more effectively.
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, certain treatments like systemic corticosteroids, chemotherapy, and investigational drugs are not allowed shortly before starting the trial. It's best to discuss your specific medications with the trial team.
Is the KRAS vaccine combined with immunotherapy safe for humans?
How is the KRAS Vaccine + Immunotherapy treatment for lung cancer different from other treatments?
What data supports the effectiveness of the KRAS Vaccine + Immunotherapy treatment for lung cancer?
Who Is on the Research Team?
Kristen Marrone, MD
Principal Investigator
Johns Hopkins University
Are You a Good Fit for This Trial?
Adults with advanced, inoperable KRAS-mutated non-small cell lung cancer (NSCLC) who haven't had prior treatment for this stage. Participants must have tumors that can be biopsied, good physical health (ECOG 0 or 1), and proper organ function. Women of childbearing age and sexually active men must agree to contraception use.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the KRAS peptide vaccine with poly-ICLC adjuvant in combination with nivolumab and ipilimumab
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term monitoring
Participants are monitored for progression free survival and T cell response
What Are the Treatments Tested in This Trial?
Interventions
- Ipilimumab
- Nivolumab
- Pooled Mutant KRAS-Targeted Long Peptide Vaccine
Ipilimumab is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lead Sponsor